D019934Concepts & IdeasE01.370.225.625.115.320E05.200.625.115.320440.998931International Normalized Ratiocmhprofilesont:personsuffixperson suffixFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson11452703Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JSJournal of clinical pharmacologyKim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001 Jul; 41(7):715-22.J Clin Pharmacol2001-07-01T00:00:002001Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.24474498Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BCPediatric blood & cancerShaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014 Jun; 61(6):1055-62.Pediatr Blood Cancer2014-01-29T00:00:002014VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.0.1347520.01291534research area of0.141290.05171634subject area for2Associate Professor1Professor25917992Wagner J, Abdel-Rahman SMPediatricsWagner J, Abdel-Rahman SM. Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review. Pediatrics. 2015 May; 135(5):e1333-6.Pediatrics2015-05-01T00:00:002015Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review.SurgeryPediatricsResearchClinicalPhD, MSAndreaGaedigkAndrea Gaedigk39.08346750000000-94.577112900000001Gaedigk, Andrea0000-0001-6968-1893Director, Pharmacogenetics Core LaboratoryPharmD, PhDJ. StevenLeederJ. Steven Leeder39.08346750000000-94.5771129000000034Leeder, J. Steven0000-0001-6688-0504Deputy Director, Children's Research InstituteChildren's Mercy Kansas CityMD, MPH, MBA, FACS, FAAPTolulopeOyetunjiTolulope A Oyetunji0.000000000000000.00000000000000157Oyetunji, Tolulope0000-0003-3039-7195Director, Surgical Scholars Program26941002Hwabejire JO, Nembhard CE, Oyetunji TA, Seyoum T, Siram SM, Cornwell EE, Greene WRAmerican journal of surgeryHwabejire JO, Nembhard CE, Oyetunji TA, Seyoum T, Siram SM, Cornwell EE, Greene WR. Abdominal compartment syndrome in traumatic hemorrhagic shock: is there a fluid resuscitation inflection point associated with increased risk? Am J Surg. 2016 Apr; 211(4):733-8.Am J Surg2015-12-31T00:00:002015Abdominal compartment syndrome in traumatic hemorrhagic shock: is there a fluid resuscitation inflection point associated with increased risk?DOJonathanWagnerJonathan B. Wagner0.000000000000000.00000000000000183Wagner, Jonathan0000000176906798Physician and Interim Division Director, Clinical Pharmacology, Toxicology & Therapeutic Innovationtrue1Physician and Interim Division Director, Clinical Pharmacology, Toxicology & Therapeutic InnovationPhysician and Interim Division Director, Clinical Pharmacology, Toxicology & Therapeutic Innovationtrue1Director, Surgical Scholars ProgramDirector, Surgical Scholars Programtrue1Director, Pharmacogenetics Core LaboratoryDirector, Pharmacogenetics Core Laboratorytrue1Deputy Director, Children's Research InstituteDeputy Director, Children's Research Institute